-

Viz.ai Appoints Radiology Advisory Board to Advance Innovation

Leading experts to help shape the future of Viz.ai’s radiology strategy and platform

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support radiologists and patients. The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology.

“I am honored to co-chair the Radiology Advisory Board and excited about Viz.ai’s commitment to customers and patients to invest in innovation that increases access to life-saving therapies,” said Kevin Abrams, MD, medical director of neuroradiology and MRI and chief of radiology at Baptist Hospital in Miami. “I am looking forward to the rich dialogue to be discussed in our inaugural meeting, exploring future ideas.”

“I’m looking forward to working with these esteemed board members to help shape Viz.ai’s Radiology Program through patient-centric vision, passion, and insights,” said Suzie Bash, MD, Co-Chair of the Viz.ai Radiology Advisory Board and Medical Director of Neuroradiology at San Fernando Valley Interventional Radiology at RADNET. “The role of artificial intelligence in radiology is growing exponentially. I’m excited by the opportunity that this foundational group of radiology experts has to apply translational, clinical AI experience to improve patient outcomes.”

The Board will assist the Viz team in informing its radiology strategy and research and development activities. Members will assess the impact of the Viz radiology program, identify clinical need for new features and modes of implementation, verify effectiveness of new capabilities, and ensure that sound scientific evidence supports projects. Additionally, the board will provide strategic advice regarding emerging science and therapeutic trends.

“The deep expertise of our Board will propel Viz.ai to new heights by driving the development of products that will support radiologists in their work and enhance patient outcomes,” said Jayme Strauss, chief clinical officer at Viz.ai. “We are immensely grateful for the expertise, time, and support of our Board members and proud to partner with them on this important endeavor.”

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,200+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Erich Sandoval
erich.sandoval@finnpartners.com
1-917-497-2867

More News From Viz.ai, Inc.

Viz.ai and Salesforce Collaborate to Transform Pharma Engagement With Real-Time Clinical Intelligence for Agentforce

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new real-time clinical intelligence service for Salesforce’s Agentforce Life Sciences. These services will power new and existing agentic solutions for life sciences customers, including a data integration that will bring Viz.ai’s real-time data, triggers, and clinical intelligence layer from across a network of nearly 2,000 hospitals covering 230...

Viz.ai Closes 2025 with Record Scale and Patient Impact, Achieving Profitability in Its Healthcare Business while Accelerating Life Sciences Growth

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a milestone year marked by record growth in its provider footprint, profitability across its healthcare business, the launch of Viz Oncology and Viz Assist, and the doubling of its life sciences business over the past 18 months. Viz.ai is now adopted in nearly 2,000 hospitals across the United States, including the majority of the 50 largest health systems, suppo...

Viz.ai and NCCN Collaborate to Integrate NCCN Guidelines into Clinical Workflows for Oncologists

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the National Comprehensive Cancer Network® (NCCN®). This collaboration integrates NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast, Prostate, and Bladder Cancer into the Viz Oncology Platform making this important information readily available to clinicians when they’re making critical decisions about patient care. Thr...
Back to Newsroom